Literature DB >> 23614603

PML in a patient treated with fumaric acid.

Ummehan Ermis, Joachim Weis, Jörg B Schulz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23614603     DOI: 10.1056/NEJMc1211805

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  67 in total

Review 1.  Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Authors:  Jens Ingwersen; Orhan Aktas; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 2.  [Immunotherapies for multiple sclerosis : review and update].

Authors:  J Havla; T Kümpfel; R Hohlfeld
Journal:  Internist (Berl)       Date:  2015-04       Impact factor: 0.743

Review 3.  Fumaric acid esters for psoriasis: a systematic review.

Authors:  D Smith
Journal:  Ir J Med Sci       Date:  2016-06-07       Impact factor: 1.568

4.  A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.

Authors:  Salim Chahin; Joseph R Berger
Journal:  J Neurovirol       Date:  2014-11-18       Impact factor: 2.643

5.  Current role of chemotherapy and bone marrow transplantation in multiple sclerosis.

Authors:  Nuria Sola-Valls; María Sepúlveda; Yolanda Blanco; Albert Saiz
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.598

6.  [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; H-P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 7.  [Systemic treatments for psoriasis and psoriatic arthritis].

Authors:  S Philipp; G Kokolakis; R Sabat
Journal:  Hautarzt       Date:  2016-06       Impact factor: 0.751

Review 8.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

9.  Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Authors:  Jonathan Zurawski; Ashley Flinn; Lindsay Sklover; Jacob A Sloane
Journal:  J Neurol       Date:  2016-05-18       Impact factor: 4.849

Review 10.  Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.

Authors:  Thorsten Bartsch; Torge Rempe; Arne Wrede; Frank Leypoldt; Wolfgang Brück; Ortwin Adams; Axel Rohr; Olav Jansen; Christian Wüthrich; Günther Deuschl; Igor J Koralnik
Journal:  Ann Neurol       Date:  2015-07-31       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.